Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery

Self-assembling non-immunoglobulin scaffold proteins are a promising class of nanoscale carriers for drug delivery and interesting alternatives to antibody-based carriers that are not sufficiently efficient in systemic administration. To exploit their potentialities in clinics, protein scaffolds nee...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2022-03, Vol.343, p.277-287
Main Authors: Serna, Naroa, Pallarès, Victor, Unzueta, Ugutz, Garcia-Leon, Annabel, Voltà-Durán, Eric, Sánchez-Chardi, Alejandro, Parladé, Eloi, Rueda, Ariana, Casanova, Isolda, Falgàs, Aïda, Alba-Castellón, Lorena, Sierra, Jorge, Villaverde, Antonio, Vázquez, Esther, Mangues, Ramón
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents
Biomaterials
Drug Carriers
Drug delivery
Drug Delivery Systems
Humans
Immunoconjugates - chemistry
Mice
Nanoconjugates
Nanoparticles
Proteins
Scaffold proteins
Self-assembling
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Self-assembling non-immunoglobulin scaffold proteins are a promising class of nanoscale carriers for drug delivery and interesting alternatives to antibody-based carriers that are not sufficiently efficient in systemic administration. To exploit their potentialities in clinics, protein scaffolds need to be further tailored to confer appropriate targeting and to overcome their potential immunogenicity, short half-life in plasma and proteolytic degradation. We have here engineered three human scaffold proteins as drug carrier nanoparticles to target the cytokine receptor CXCR4, a tumoral cell surface marker of high clinical relevance. The capability of these scaffolds for the selective delivery of Monomethyl auristatin E has been comparatively evaluated in a disseminated mouse model of human, CXCR4+ acute myeloid leukemia. Monomethyl auristatin E is an ultra-potent anti-mitotic drug used against a range of hematological neoplasias, which because of its high toxicity is not currently administered as a free drug but as payload in antibody-drug conjugates. The protein nanoconjugates generated here offer a collective strength of simple manufacturing process, high proteolytic and structural stability and multivalent ligand receptor interactions that result in a highly efficient and selective delivery of the payload drug and in a potent anticancer effect. The approach shown here stresses this class of human scaffold proteins as promising alternatives to antibodies for targeted drug delivery in the rapidly evolving drug development landscape. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2022.01.017